Xin Chen^*, Mingzhe Li^†, Hongwei Zhou^*, Li Zhang^*

Oncology Research, Vol.27, No.4, pp. 431-437, 2019, DOI:10.3727/096504018X15201058168730

Abstract MicroRNA-132 (miR-132) has been demonstrated to be a tumor suppressor in several types of tumors. However, the expression and the role of miR-132 in human thyroid cancer are still poorly understood. The aim of the present study was to examine the potential roles and molecular mechanism of miR-132 in thyroid cancer. We found that miR-132 expression levels were significantly downregulated in thyroid cancer tissues and cell lines. Function assays showed that overexpression of miR-132 in TPC1 cells inhibited cell proliferation, migration, and invasion. Forkhead box protein A1 (FOXA1) was identified as a direct target of miR-132 in thyroid cancer cells.… More >

Xin Chen^*, Mingzhe Li^†, Hongwei Zhou^*, Li Zhang^*

Oncology Research, Vol.28, No.9, pp. 965-967, 2020, DOI:10.3727/096504022X16414984936764

Abstract MicroRNA-132 (miR-132) has been demonstrated to be a tumor suppressor in several types of tumors. However, the expression and the role of miR-132 in human thyroid cancer are still poorly understood. The aim of the present study was to examine the potential roles and molecular mechanism of miR-132 in thyroid cancer. We found that miR-132 expression levels were significantly downregulated in thyroid cancer tissues and cell lines. Function assays showed that overexpression of miR-132 in TPC1 cells inhibited cell proliferation, migration, and invasion. Forkhead box protein A1 (FOXA1) was identified as a direct target of miR-132 in thyroid cancer cells.… More >

Federico Cappellacci^*, Gian Luigi Canu, Stefano Piras, Giacomo Anedda, Pietro Giorgio Calò, Fabio Medas

Oncologie, Vol.24, No.1, pp. 35-50, 2022, DOI:10.32604/oncologie.2022.020864

Abstract Thyroid cancer is the fifth most common cancer in the USA, with differentiated subtype accounting for more than 95% of neoplasm. Surgery remains the mainstay of treatment, either with lobectomy or total thyroidectomy. In the last decades, many technological innovations have been introduced in this field. The aim of this review is to illustrate the most recent advances regarding the classical surgical approach, particularly regarding hemostatic devices, parathyroid identification with fluorescence systems, intraoperative identification of lymph node metastases, and intraoperative neuromonitoring. More >

Hyeong Won Yu¹, Muhammad Afzal², Maqbool Hussain², Hyungju Kwon³, Young Joo Park⁴, June Young Choi^1,*, Kyu Eun Lee⁵

CMC-Computers, Materials & Continua, Vol.67, No.1, pp. 1241-1251, 2021, DOI:10.32604/cmc.2021.014910

Abstract Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes.… More >

Chuanwei Xu¹, Renju Ding², Chuanping Xu^3,*

Oncologie, Vol.22, No.1, pp. 43-51, 2020, DOI:10.32604/oncologie.2020.012445

Abstract To analyze the effects of different surgical procedures for the treatment of thyroid cancer on the expression levels of serum interleukin-17 (IL-17), IL-35, soluble interleukin-2 receptor (SIL-2R), and the prognostic factors. Seventy-eight patients with differentiated thyroid cancer were selected and grouped as control group (CG) (n = 39, underwent subtotal thyroidectomy) and observation group (OG) (n = 39, underwent total thyroidectomy). The serum IL-17, IL-35, and SIL- 2R expression levels; the incidence of complications; and the differentiated thyroid carcinoma (DTC) relapse rate were compared between the two groups. The serum IL-17 and SIL-2R levels were lower in the OG than… More >